STOCKS TELEGRAPH

Tag: XERS

  • Is XERS Stock a Good Buy in 2025? Key Insights for Investors

    Is XERS Stock a Good Buy in 2025? Key Insights for Investors

    Xeris Biopharma Holdings (NASDAQ: XERS) has been gaining attention in the biotech industry due to its innovative drug pipeline and strong growth potential. As investors look toward 2025, many are wondering: Is XERS stock a good buy in 2025? This article explores Xeris’ business model, financials, growth drivers, risks, and expert opinions to help you determine if it’s a solid investment.

    Xeris Biopharma Overview & Business Model

    Xeris Biopharma is a biotech company specializing in ready-to-use injectable drug formulations that improve patient adherence and reduce the need for refrigeration. Its proprietary XeriSol™ and XeriJect™ technology platforms enhance the stability and delivery of various biologics and small molecules.

    Key Revenue Sources:

    • Gvoke HypoPen (glucagon for severe hypoglycemia treatment)
    • Keveyis (the first FDA-approved treatment for primary periodic paralysis)
    • Recorlev (for Cushing’s syndrome)
    • Partnerships and licensing agreements with pharmaceutical companies

    XERS Stock Performance & Financial Analysis

    Stock Snapshot:

    • Current Price: $5.03
    • 52-Week Range: $1.69 – $5.07
    • Market Cap: $774.32M
    • P/E Ratio: -13.55
    • EPS (TTM): -$0.37
    • Revenue (TTM): $182.68 million

    Financial Highlights – Q2 (Dec 2024) Report:

    • Revenue: $60.099 million (35.39% YoY growth)
    • Net Income: -$5.11 million (61.81% YoY improvement)
    • Diluted EPS: -$0.03
    • Cash & Equivalents: $71.62 million
    • Debt-to-Equity Ratio: -1.84

    Xeris has demonstrated strong revenue growth, fueled by increasing product adoption. However, profitability remains a challenge, primarily due to continued investments in R&D and operational expansion. The company’s financials indicate a steady trajectory toward reducing losses, a critical factor for investors evaluating long-term potential.

    Growth Drivers for XERS Stock in 2025

    Expanding Drug Pipeline

    • Xeris is advancing multiple clinical trials targeting endocrinology, neurology, and metabolic disorders.
    • Potential FDA approvals and label expansions in 2025 could drive revenue growth.

    Strategic Partnerships & Licensing Deals

    • Collaborations with big pharma companies could unlock new revenue streams.
    • Licensing out its XeriSol™ and XeriJect™ platforms may generate milestone payments.

    Rising Demand for Ready-to-Use Injectables

    • The biopharmaceutical industry is shifting toward patient-friendly drug delivery methods.
    • Xeris’ innovative formulations provide a competitive edge over traditional injectable medications.

    Potential Risks & Challenges

    Regulatory & Clinical Trial Risks

    • Any delays or failures in FDA approvals could negatively impact stock performance.

    Financial Sustainability

    • Xeris is not yet profitable, relying on external funding and debt to support operations.

    Competition from Larger Biotech Firms

    • Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the diabetes and endocrinology market.
    • Xeris must differentiate its products to capture market share.

    Analyst Ratings & Price Target Predictions

    XERS Recent Analyst Ratings: Strong Bullish Sentiment

    Analysts remain optimistic about Xeris Biopharma Holdings (XERS), with several firms raising their price targets and maintaining bullish ratings. The latest analyst ratings suggest strong growth potential, reflecting confidence in the company’s expanding product pipeline and revenue trajectory.

    Latest Analyst Ratings – March 7, 2025

    • Roanna Ruiz (Leerink Partners): Maintains an Outperform rating, raising the price target from $5.00 to $6.00, indicating potential upside.
    • Oren Livnat (HC Wainwright & Co.): Reiterates a Buy rating, with an aggressive price target jump from $6.60 to $8.00, reflecting strong conviction in Xeris’ growth outlook.
    • David Amsellem (Piper Sandler): Reiterates a Neutral rating, adjusting the price target from $3.00 to $4.00, signaling a cautious stance despite some upside.
    • Chase Knickerbocker (Craig-Hallum): Maintains a Buy rating, increasing the price target from $5.00 to $6.50, reinforcing a positive long-term outlook.

    The analyst consensus suggests a bullish trajectory for XERS stock, with multiple firms raising their price targets. While some remain cautious, the upward revisions indicate confidence in Xeris’ future performance, making it a compelling watchlist candidate for 2025.

    Institutional & Retail Investor Sentiment

    Institutional Ownership: Who’s Backing Xeris Biopharma (XERS)?

    Institutional investors play a crucial role in shaping market sentiment, and Xeris Biopharma Holdings (XERS) has gained solid backing from major financial institutions. Currently, 42.87% of XERS shares are held by institutional investors, reflecting strong confidence in the company’s prospects.

    Top Institutional Investors

    • Principal Financial Group Inc. leads the pack, holding 89.62K shares valued at $198.06K, representing a 0.06% stake in Xeris Biopharma.
    • AllianceBernstein L.P. follows closely, with 80.42K shares valued at $177.73K, also translating to a 0.06% stake in the company.

    Investor Sentiment on Xeris Biopharma (XERS) – What’s the Market Saying?

    Investor sentiment plays a critical role in determining short-term price movements, and Xeris Biopharma (XERS) stock has seen shifting sentiment trends over different timeframes.

    Short-Term Sentiment (1 Week & 1 Month)

    • The one-week sentiment score currently stands at 5.26, reflecting data from 22 social media posts but no news articles or opinion pieces.
    • This marks a significant decline of -15.78 points from 21.04 a week ago, indicating a drop in positive discussions surrounding XERS.
    • Over the past month, the sentiment trend has mirrored this movement, with the score falling from 21.04 to 5.26.
    • The sentiment score has fluctuated between 5.26 and 33.1 over the past month.

    Mid-Term Sentiment (6 Months)

    • The six-month sentiment score presents a more optimistic picture, currently at 39.2.
    • This figure is derived from 127 social media posts, 4 news articles, and 1 opinion article, reflecting higher investor engagement over the long term.
    • The sentiment score has ranged between 0 and 53.43, showing broad fluctuations in investor perception.

    The Verdict: Should You Buy, Hold, or Sell XERS Stock in 2025?

    With all the data analyzed—including financial performance, institutional ownership, sentiment trends, and analyst ratings—let’s break down whether Xeris Biopharma Holdings (XERS) stock is a buy, hold, or sell in 2025.

    Bullish Case: Why XERS Stock Could Be a Strong Buy

    Revenue Growth & Market Expansion
    Xeris reported strong YoY revenue growth of 35.39% in Q2 2024, indicating solid demand for its pharmaceutical products. Expanding partnerships and commercialization of innovative therapies could drive further revenue gains.

    Analyst Optimism & Price Target Upside
    Multiple analysts have maintained “Buy” or “Outperform” ratings on XERS stock, with price targets increasing from $5.00 to $8.00, indicating strong upside potential.

    Institutional Confidence
    Financial institutions hold 42.87% of XERS shares, with notable investors like Principal Financial Group and AllianceBernstein showing interest, which suggests institutional confidence in Xeris’ long-term growth.

    Potential for Profitability
    While Xeris still reports net losses, its reduced loss margins and higher gross revenue indicate the company is moving toward profitability. Continued cost management and revenue expansion could help Xeris break even sooner than expected.

    Bearish Case: Why XERS Stock May Face Challenges

    High R&D and Operating Costs
    Despite revenue growth, net losses remain a concern (-$5.11M in Q2 2024), primarily due to high research & development (R&D) and operational expenses. Investors should monitor whether Xeris can scale operations efficiently.

    Stock Volatility & Sentiment Decline
    Investor sentiment dropped significantly from 21.04 to 5.26 in one week, reflecting short-term uncertainty. This could indicate near-term price fluctuations and risk.

    Negative EPS & Valuation Concerns
    Xeris still has a negative EPS (-$0.03 diluted EPS) and a P/E ratio of -13.55, suggesting it is not yet profitable. The stock remains speculative for investors seeking consistent earnings.

    Final Recommendation: Buy, Hold, or Sell?

    • Buy if you are a long-term investor willing to tolerate volatility and believe in Xeris’ growth trajectory, revenue expansion, and future profitability.
    • Hold if you are waiting for profitability improvements and cost reductions before making a stronger commitment.
    • Sell if you prioritize stable, dividend-paying stocks or want to avoid speculative biotech investments.

    Conclusion: Is XERS Stock a Good Buy in 2025?

    Given Xeris Biopharma’s impressive revenue growth, strong analyst support, and institutional confidence, the stock presents an attractive long-term opportunity. However, its ongoing losses and stock volatility make it a riskier short-term investment. Investors seeking high-growth potential may consider buying, while those preferring stable returns should wait for further financial improvements.

  • Xeris Biopharma Holdings, Inc. (XERS) Stock Tumbling in Aftermarket, Here’s What you Should Know.

    Xeris Biopharma Holdings, Inc. (XERS) Stock Tumbling in Aftermarket, Here’s What you Should Know.

    Xeris Biopharma Holdings, Inc. (XERS) is an innovative biotherapeutics company. The company is engaged in the development and marketing of treatments for patients with gastroenterological, neurological, and endocrinological issues. The lead product of the company includes Gvoke and Keveyis used for treating severe hypoglycemia and primary periodic paralysis respectively.

    The price of XERS stock during the regular trading on January 28, 2021, was $2.07 with an increase of 3.50%. At last check in the aftermarket, the stock fell by 9.18%.

    XERS: Events and Happenings

    On January 28, 2022, XERS reported about the submission of form 8-K or a report of unscheduled corporate events or material events. On January 18, 2022, XERS reported about the business update and reiterated its 2021 net sales. The initial full-year 2021 net sales were expected to be approximately $76-80 million (55% increase than 2020).

    On Jan. 13, 2022, XERS subsidiary selected PANTHERx Rare as the proprietary pharmacy distributor for Recorlev. It is FDA approved for treating endogenous hypercortisolemia in Cushing’s syndrome patients. On January 6, 2022, XERS reported that the company’s Executives presented at the Virtual H.C. Wainwright BioConnect 2022 conference held on January 10-13, 2022.

    On January 3, 2022, XERS reported about its entry into a contract of securities acquisition of a private placement for net proceeds of up to $30 million. The company issued 10,238,908 shares of its common stock at an acquisition price of $2.93 per share. Also, it issued the warrants for the acquisition of 5,119,454 shares at an exercise price of $3.223 per share.

    On December 30, 2021, XERS reported about the approval of the safety and effectiveness of Recorlev by the FDA. On December 16, 2021, XERS reported about the launch of Ogluo by its marketing collaborator ‘Tetris Pharma’ in the UK.

    XERS: Key Financials

    On November 10, 2021, XERS reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic ad diluted net loss per share in Q3 2021 was $26.0 million or $0.39 compared to $16 million or $0.35 in the same period of 2020.

    Assets

    Total current assets recorded for the company in Q3 2021 were $124.3 million.

    Conclusion

    XERS stock dipped 32% in the last six months due to negative economic growth conditions as a result of COVID-19. The analysts are of the view that the company’s policies to attract investors are sound and will enhance its reputation in the future. The current aftermarket decline in stock price is likely being associated with the 8-K form submission.

  • FDA Approval of Recorlev: Xeris Biopharma Holdings Inc. (XERS) Bullish After Hours

    FDA Approval of Recorlev: Xeris Biopharma Holdings Inc. (XERS) Bullish After Hours

    Xeris Biopharma Holdings Inc. (XERS) became bullish on the news of its Recorlev® receiving FDA approval for Cushing’s syndrome patients. Consequently, the stock was trading at $3.15 apiece with a huge increase of 29.63% in the after-hours.

    During the regular session, the stock fluctuated between a high of $2.63 and a low of $2.42 at 9.28 million shares. XERS closed the session with a decrease of 3.19% at $2.43 on December 30. Following the news, the stock saw a reversal as it became bullish after hours, gaining big at 6.01M shares.

    Xeris Biopharma Holdings Inc. has a market capitalization of $313.02 million. Currently, the company has 124.71 million shares outstanding in the market.

    XERS’ FDA Approval of Recorlev

    Recorlev® or Levoketoconzaole is a new therapeutic option for the management of endogenous Cushing’s syndrome patients. It is a severe and potentially life-threatening rare disease. It is caused by chronic elevated cortisol exposure, usually due to a pituitary gland benign tumor. Moreover, it causes multisystem complications like diabetes, high cholesterol, and B.P, the fragility of multiple tissues including blood vessels, skin, muscle, and bone, and psychological disorders as well.

    On Thursday, XERS disclosed that the U.S FDA has approved Recorlev® (levokeyoconazole). Further, it is approved for treating endogenous hypercortisolemia in Cushing’s syndrome’s adult patients with no option of surgery or noncurative surgery.

    In addition, the basis of the approval was the safety and efficacy data of Recorlev® from two Phase 3 studies of a total of 166 patients. Both the studies achieved their primary as well as key secondary endpoints. Moreover, the studies also resulted in a significant decrease in the mean urinary free cortisol concentrations without a dose increase. Hence, treatment with Recorlev® causes reduction and normalization of cortisol levels.

    Financial Analysis

    On November 10, the company announced its financial results for the third quarter of 2021, which ended on September 30.

    In the third quarter of 2021, XERS’s net sales of Gvoke HypoPen® and Gvoke pre-filled syringe were $11.0 million. This compares to $9.4 million in the third quarter of 2020.

    Moreover, the cost of goods sold in the third quarter of 2021, was $3.2 million.

    Furthermore, the company incurred a net loss of $26.0 million in the third quarter of 2021. Consequently, the net loss per basic and diluted shares in the third quarter of 2021, was $0.39. This includes transaction-related expenses of $2.3 million or $0.03 per share.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.

  • Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country, a mammoth logistics task in favor of what could be the most difficult immunization campaign in history.

    In delivering the vaccine, which is delicate and needs careful care, FedEx and UPS would play key roles. At the terminal, shipments can gain preferential entry. If a plane arrives to land with vaccinations, other passenger flights may have to loop around to wait for their chance.

    The arrival of the first vaccines comes as the virus continues to rage through the USA, with more than 207,000 new cases identified on Saturday by authorities. That took the number to more than 16 million, the most in the world by far. For the first time on Wednesday, more than 3,000 deaths were reported, and the country’s number is nearing 300,000.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were trading up 41.55% at $3.10 at the time of writing on Friday. The firm on November 25, 2020 announced common stock purchase agreement for up to $47 million with Lincoln Park Capital.

    vTv Therapeutics Inc. (NASDAQ:VTVT) share price went from a low point around $1.44 to briefly over $4.23 in past 52 weeks, though shares have since pulled back to $3.10. VTVT market cap has remained high, hitting $161.79M at the time of writing, giving it price-to-sales ratio of more than 7350.

    If we look at the recent analyst rating VTVT, H.C. Wainwright initiated coverage on VTVT shares with a Buy rating.

    aTyr Pharma Inc. (LIFE) last closed at $4.64, in a 52-week range of $2.13 to $7.62. The company on November 13, 2020 released third quarter results and provided a corporate update.

    ADiTx Therapeutics Inc. (ADTX) stock soar by 3.77% to $2.48. The firm reported on December 8, 2020, that it will present at the 13th annual LD Micro main event conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST.

    9 Meters Biopharma Inc. (NASDAQ:NMTR) Shares headed falling, lower as much as -11.75%.

    Iterum Therapeutics plc (NASDAQ:ITRM) rose 11.72% after gaining more than $0.1 on Friday. The biotechnology firm declared on December 7,2020, filing of US patent application based on favorable written opinion of the International Search Authority.

    Vaxart Inc. (VXRT) last closed at $7.44, in a 52-week range of $0.28 to $17.49.

    Catabasis Pharmaceuticals Inc. (CATB) stock soar by 14.51% to $2.21. The most recent rating by Wedbush, on November 02, 2020, is at a Neutral.

    Advaxis Inc. (NASDAQ:ADXS) Shares headed rising, higher as much as 3.56%. The company on November 27, 2020 reported the closing of $9.2 million public offering. The most recent rating by Barclays, on August 03, 2016, is at an Overweight.

    Xeris Pharmaceuticals Inc. (NASDAQ:XERS) rose 11.74% after gaining more than $0.48 on Friday following an announcement from the company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Novavax Inc. (NVAX) last closed at $124.88, in a 52-week range of $3.65 to $189.40. The firm on December 9, 2020, declared the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Analysts have a consensus price target of $186.20.

    Corbus Pharmaceuticals Holdings Inc. (CRBP) stock soar by 1.52% to $1.34. The most recent rating by ROTH Capital, on September 08, 2020, is at a Neutral.

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares headed falling, lower as much as -1.23%. The most recent rating by Mizuho, on April 22, 2020, is at a Neutral.

    Novan Inc. (NASDAQ:NOVN) rose 1.10% after gaining more than $0.01 on Friday.

    Nabriva Therapeutics plc (NBRV) last closed at $2.44, in a 52-week range of $3.26 to $18.29. The company recently announced pricing of $15 million public offering.

    Salarius Pharmaceuticals Inc. (SLRX) stock drop by -31.34% to $0.92 after declaring that it has entered into agreements with several institutional and accredited investors to exercise of warrants for $3.5 million of gross proceeds to be used for ongoing development of Seclidemstat. The most recent rating by Ladenburg Thalmann, on April 27, 2020, is at a Buy.